Pre-analytical Protocol for Measuring Alzheimer's Disease Biomarkers in Fresh CSF

Overview

Journal Alzheimers Dement (Amst)

Date 2020 Dec 23

PMID 33354617

Citations 18

Authors

Oskar Hansson

Sandra Rutz

Henrik Zetterberg

Ekaterina Bauer

Teresa Hahl

Ekaterina Manuilova

Mehmet Can Mert

Simone Wahl

Kaj Blennow

Erik Stomrud

Affiliations

Soon will be listed here.

Abstract

Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF).

Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays.

Results: Amyloid beta (Aβ) levels varied by tube type, using a low-bind FBT reduced variation. Aβ levels were higher with no mixing versus roller/inversion mixing. Aβ levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ levels were less strongly affected. Phospho-tau and total-tau levels were largely unaffected.

Discussion: We propose an easy-to-use, standardized, routine-use pre-analytical protocol, using low-bind FBTs, for measuring AD CSF biomarkers in clinical practice.

Citing Articles

Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo.

Binette A, Mammana A, Wisse L, Rossi M, Strandberg O, Smith R Alzheimers Dement. 2024; 20(11):7624-7634.

PMID: 39258841 PMC: 11567871. DOI: 10.1002/alz.14225.

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.

Bali D, Hansson O, Janelidze S Alzheimers Res Ther. 2024; 16(1):31.

PMID: 38331843 PMC: 10851521. DOI: 10.1186/s13195-024-01391-1.

Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.

Heidebrink J, Paulson H Annu Rev Med. 2024; 75:99-111.

PMID: 38285515 PMC: 10926277. DOI: 10.1146/annurev-med-051022-043645.

Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease.

Giangrande C, Delatour V, Andreasson U, Blennow K, Gobom J, Zetterberg H Alzheimers Dement (Amst). 2023; 15(3):e12465.

PMID: 37600860 PMC: 10432775. DOI: 10.1002/dad2.12465.

Alzheimer's disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C.

Konen F, Maier H, Neyazi A, Bleich S, Neumann K, Skripuletz T Neurol Res Pract. 2023; 5(1):30.

PMID: 37381021 PMC: 10308606. DOI: 10.1186/s42466-023-00257-5.

References

Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O . Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017; 52:196-213. DOI: 10.1016/j.neurobiolaging.2016.02.034. View

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M . Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem. 2019; 72:30-38. DOI: 10.1016/j.clinbiochem.2019.05.005. View

Bittner T, Zetterberg H, Teunissen C, Ostlund Jr R, Militello M, Andreasson U . Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2015; 12(5):517-26. DOI: 10.1016/j.jalz.2015.09.009. View

Beach T, Monsell S, Phillips L, Kukull W . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4):266-73. PMC: 3331862. DOI: 10.1097/NEN.0b013e31824b211b. View

Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C . How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ/Aβ ratio. Alzheimers Dement. 2017; 13(8):885-892. DOI: 10.1016/j.jalz.2017.01.010. View

Jack Jr C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. PMC: 3622225. DOI: 10.1016/S1474-4422(12)70291-0. View

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein M, Bowser R . Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomark Med. 2012; 6(4):409-17. DOI: 10.2217/bmm.12.39. View

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View

10.

Vanderstichele H, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V . Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes. J Alzheimers Dis. 2016; 53(3):1121-32. PMC: 4981898. DOI: 10.3233/JAD-160286. View

11.

Sperling R, Mormino E, Johnson K . The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014; 84(3):608-22. PMC: 4285623. DOI: 10.1016/j.neuron.2014.10.038. View

12.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

13.

Janelidze S, Stomrud E, Brix B, Hansson O . Towards a unified protocol for handling of CSF before β-amyloid measurements. Alzheimers Res Ther. 2019; 11(1):63. PMC: 6642586. DOI: 10.1186/s13195-019-0517-9. View

14.

Blennow K, Zetterberg H . Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018; 284(6):643-663. DOI: 10.1111/joim.12816. View

15.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

16.

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

17.

James B, Wilson R, Boyle P, Trojanowski J, Bennett D, Schneider J . TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016; 139(11):2983-2993. PMC: 5091047. DOI: 10.1093/brain/aww224. View

18.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

19.

Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A . Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clin Chim Acta. 2015; 449:9-15. DOI: 10.1016/j.cca.2015.05.024. View

20.

Bjerke M, Engelborghs S . Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. J Alzheimers Dis. 2018; 62(3):1199-1209. PMC: 5870045. DOI: 10.3233/JAD-170680. View